In a report released today, David Lewis from Morgan Stanley maintained a Buy rating on Johnson & Johnson (JNJ), with a price target of $160.00. The company’s shares closed last Monday at $124.30.
According to TipRanks.com, Lewis is a 4-star analyst with an average return of 3.0% and a 53.9% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Baxter International.
Currently, the analyst consensus on Johnson & Johnson is a Strong Buy with an average price target of $161.25, implying a 32.6% upside from current levels. In a report released today, Citigroup also maintained a Buy rating on the stock with a $150.00 price target.
See today’s analyst top recommended stocks >>
Based on Johnson & Johnson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $20.75 billion and net profit of $4.01 billion. In comparison, last year the company earned revenue of $20.39 billion and had a net profit of $3.04 billion.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Read More on JNJ:
